The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density

Chronic use of proton-pump inhibitors (PPIs) has become a mainstay of therapy in common gastrointestinal diseases. A causal relationship between chronic PPI use and development of osteoporosis remains unproven. The aim of this study was to determine whether PPI users are more likely to develop alter...

Full description

Saved in:
Bibliographic Details
Published in:Risk management and healthcare policy 2019-01, Vol.12, p.349-355
Main Authors: Fattahi, Mohammad Reza, Niknam, Ramin, Shams, Mesbah, Anushiravani, Amir, Taghavi, Seyed Alireza, Omrani, Gholamhossein Ranjbar, Mahmoudi, Laleh
Format: Article
Language:English
Subjects:
Age
Bone density
dyspepsia
Energy
Family medical history
FDA approval
Fractures
Gastroesophageal reflux
metabolic bone diseases
Original Research
Osteoporosis
proton pump inhibitors
Studies
Ulcers
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic use of proton-pump inhibitors (PPIs) has become a mainstay of therapy in common gastrointestinal diseases. A causal relationship between chronic PPI use and development of osteoporosis remains unproven. The aim of this study was to determine whether PPI users are more likely to develop alterations in bone density. In an analytical cross sectional study, patients who used PPIs for more than 2 years because of long-term gastroesophageal reflux disease (GERD) were recruited. PPI users were healthy people except for GERD. The compression group was randomly derived from an age-, sex- and physical activity-matched group from a healthy population in the National Registry of Osteoporosis who had not used PPIs in the previous 2 years. Bone mineral density was measured with dual-energy X-ray absorptiometry. Data regarding BMD and bone mineral content (BMC) of three regions: femoral neck, total hip, and the lumbar spine (L1-L4) were gathered and recorded. The World Health Organization (WHO) classification was used for definition of osteopenia and osteoporosis. A total of 394 participants (133 PPI users and 261 comparison group) were enrolled. The median duration of PPI use was 6.7 (2-31) years. The mean age ± SD of PPI users and comparison group was 48.38 ± 11.98 and 47.86 ± years, respectively (P = 0.681). There was no significant difference in baseline characteristics and age distribution between the two groups. The BMC levels were significantly lower in PPI users in all three regions: lumbar spine, total hip, and femoral neck (P
ISSN:1179-1594
1179-1594
DOI:10.2147/RMHP.S223118